Abstract 1059P
Background
The impact of the duration of tumor persistence within the host – tumor longevity (TL) – on patient (pt) outcomes under immune checkpoint inhibitors (ICIs) is unexplored. We hypothesized that this time parameter may influence ICIs efficacy. We investigated this association in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and renal/urothelial cancer (R/UC) pts.
Methods
Retrospective, observational study including adult pts with primary/recurrent HNSCC, NSCLC, R/UC receiving ICIs (≥first line) in 2 Italian centers. Endpoints were the association between TL and: 1) progressive disease (PD) vs. complete response (CR)/ partial response (PR)/ stable disease (SD); 2) Common Terminology Criteria for Adverse Events (CTCAE) G≥3 toxicity; 3) overall survival (OS). Univariable/multivariable logistic regression model (for PD, toxicity) and Cox proportional hazards model (for OS) were used. TL, defined as time from cancer histological diagnosis to ICIs start, was included as continuous variable using 3 knots restricted cubic spline, comparing third (Q3) vs. first (Q1) quartiles.
Results
304 pts, diagnosed in 2002-2022, started ICIs in 2014-2022. TL had a right-skewed distribution [median: 15.3 (Q1-Q3, 5.5; 33.1) months]. CR, PR, SD, PD occurred in 16 (5.3%), 90 (29.6%), 65 (21.4%), 133 (43.7%) pts, respectively; G≥3 toxicity was reported in 16 (5.3%) pts and 231 (76.0%) pts died. Multivariable models adjusted for relevant variables (Table) suggested that longer TL was associated with lower PD odds (Odds Ratio [OR] Q3 vs. Q1 = 0.31; 95% CI 0.12; 0.81, p = 0.004), higher G≥3 toxicity odds (OR = 1.27; 95% CI 0.39; 4.12), lower death risk (Hazard Ratio = 0.79; 95% CI 0.49; 1.28). Table: 1059P
| Descriptive statistics (N=304) | ||
| Sex | Male | 243 (79.9%) |
| Age at diagnosis (years) | Mean (SD) | 64.7 (10.4) |
| Smoking history | Yes | 226 (74.3%) |
| No | 57 (18.8%) | |
| Unknown | 21 (6.9%) | |
| Primary site | NSCLC | 138 (45.4%) |
| HNSCC | 112 (36.5%) | |
| R/UC | 54 (17.8%) | |
| Stage at diagnosis | IV | 199 (65.5%) |
ConclusionsOur real-world, hypothesis-raising results indicate that longer TL may lead to improved response to ICIs, higher risk of G≥3 toxicity and longer OS. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyThe authors. FundingAuthors at Niguarda Cancer Center are supported by Fondazione Oncologia Niguarda ETS. DisclosureA. Sartore Bianchi: Financial Interests, Personal, Advisory Board: Amgen, Servier, Novartis; Financial Interests, Personal, Invited Speaker: Bayer, Guardant Health, Pierre Fabre. S. Siena: Financial Interests, Advisory Board: Agenus, Amgen, AstraZeneca, Bayer, BMS, CheckmAb, Clovis, Daiichi Sankyo, Merck, Novartis, Roche-Genentech, Seattle Genetics. L.F.L. Licitra: Financial Interests, Personal, Advisory Board, for expert opinion in advisory boards: AstraZeneca, Bayer, BMS, Eisai, MSD, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd, Novartis, Roche, Debiopharm International SA, Sobi, Incyte Biosciences Italy srl, Doxa Pharma srl, Amgen, Nanobiotics, GSK; Financial Interests, Institutional, Research Grant, Funds received by my institution for clinical studies and research activities in which I am involved: AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, F. Hoffmann-La Roche ltd, IRX Therapeutics, Medpace, Merck-Serono, Merck Healthcare KGaA, MSD, Novartis, Pfizer, Roche, Adlai Nortye. All other authors have declared no conflicts of interest. Resources from the same session1045P - The association of human leukocyte antigen variants in immune-related toxicity and efficacy in Chinese lung cancer patients treated with immune checkpoint inhibitorsPresenter: Yongchang Zhang Session: Poster session 03 1046P - Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapyPresenter: Yi Hu Session: Poster session 03 Resources: Abstract 1047P - Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritisPresenter: Michel Obeid Session: Poster session 03 1048P - Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter studyPresenter: Danielle Delombaerde Session: Poster session 03 1049P - Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective studyPresenter: Mariam Shalaby Session: Poster session 03 1050P - Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAEPresenter: Sarah Roffeis Session: Poster session 03 1051P - Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitorsPresenter: Antoine Italiano Session: Poster session 03 Resources: Abstract 1052P - Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signaturesPresenter: Elisabetta Nale Session: Poster session 03 1053P - The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based studyPresenter: Abdulrahman Alghabban Session: Poster session 03 1054P - CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatmentPresenter: Mariano Provencio Pulla Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|